Disclosed is the use of diphenylhydantoin compounds represented by the formulae depicted herein and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of hyperproliferative disorder selected from prostate cancer (particularly hormone sensitive prostate cancer), benign prostate hyperplasia, breast cancer and ovarian cancer.